Literature DB >> 25301672

CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL).

Fiona Pui San Liaw1, Lai Ching Lau, Alvin Soon Tiong Lim, Tse Hui Lim, Geok Yee Lee, Sim Leng Tien.   

Abstract

The present study was designed to compare abnormality detection rates using DSP30 + IL2 and 12-O-Tetradecanoylphorbol-13-acetate (TPA) in Asian patients with B-CLL. Hematological specimens from 47 patients (29 newly diagnosed, 18 relapsed) were established as 72 h-DSP30 + IL2 and TPA cultures. Standard methods were employed to identify clonal aberrations by conventional cytogenetics (CC). The B-CLL fluorescence in situ hybridization (FISH) panel comprised ATM, CEP12, D13S25, and TP53 probes. DSP30 + IL2 cultures had a higher chromosomal abnormality detection rate (67 %) compared to TPA (44 %, p < 0.001). The mean number of analyzable metaphases and abnormal metaphases per slide was also higher (p < 0.005, p < 0.001, respectively). Culture success rate, percentage of complex karyotype, and percentage of non-clonal abnormal cell were not significantly different (p > 0.05). Thirteen cases with abnormalities were found exclusively in DSP30 + IL2 cultures compared to one found solely in TPA cultures. DSP30 + IL2 cultures were comparable to the FISH panel in detecting 11q-, +12 and 17p- but not 13q-. It also has a predilection for 11q- bearing leukemic cells compared to TPA. FISH had a higher abnormality detection rate (84.1 %) compared to CC (66.0 %) with borderline significance (p = 0.051), albeit limited by its coverage. In conclusion, DSP30 + IL2 showed a higher abnormality detection rate. However, FISH is indispensable to circumvent low mitotic indices and detect subtle abnormalities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301672     DOI: 10.1007/s12185-014-1681-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  43 in total

1.  Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County.

Authors:  R P Gale; W Cozen; M T Goodman; F F Wang; L Bernstein
Journal:  Leuk Res       Date:  2000-08       Impact factor: 3.156

2.  Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

Authors:  John C Byrd; Lisa Smith; Marcy L Hackbarth; Ian W Flinn; Donn Young; John H Proffitt; Nyla A Heerema
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

3.  Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.

Authors:  Kimberly J Stockero; Stephanie R Fink; Stephanie A Smoley; Sarah F Paternoster; Tait D Shanafelt; Timothy G Call; Clive S Zent; Daniel L Van Dyke; Neil E Kay; Gordon W Dewald
Journal:  Cancer Genet Cytogenet       Date:  2006-04-15

4.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

5.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.

Authors:  C Haferlach; F Dicker; S Schnittger; W Kern; T Haferlach
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

6.  Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

Authors:  T Decker; F Schneller; T Sparwasser; T Tretter; G B Lipford; H Wagner; C Peschel
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

7.  Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence--clinical implication and comparison between the West and the East.

Authors:  Shang-Ju Wu; Chien-Ting Lin; Sheng-Yi Huang; Fen-Yu Lee; Ming-Chi Liu; Hsin-An Hou; Chien-Yuan Chen; Bor-Sheng Ko; Wen-Chien Chou; Ming Yao; Jih-Luh Tang; Woei Tsay; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2013-02-17       Impact factor: 3.673

8.  Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.

Authors:  T Decker; F Schneller; M Kronschnabl; T Dechow; G B Lipford; H Wagner; C Peschel
Journal:  Exp Hematol       Date:  2000-05       Impact factor: 3.084

9.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

10.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more
  1 in total

1.  Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis.

Authors:  Wangui Yu; Bing Lu; Hengwen Zhang; Yanxiang Zhang; Jin Yan
Journal:  Biomed Rep       Date:  2016-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.